Hepatitis C Infection Clinical Trial
Official title:
A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naïve HCV Infected Adults
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
This is a First-in-human, Two-stage, Multi-centre study. Part A is an open-label, single ascending dose study in fed or fasted subjects and Part B is a randomized, placebo-controlled multiple ascending dose study. The study is designed to evaluate the safety and tolerability of ascending doses of SB 9200 given as monotherapy for up to 14 days to subjects with chronic Hepatitis C infection, and to determine the pharmacokinetic and pharmacodynamic relationship over this dose range. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01771653 -
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|
N/A | |
| Recruiting |
NCT03601546 -
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
|
||
| Completed |
NCT02362217 -
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
|
Phase 1 | |
| Completed |
NCT00513461 -
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
|
Phase 2 | |
| Active, not recruiting |
NCT02143401 -
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02582632 -
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
|
Phase 3 | |
| Terminated |
NCT01532908 -
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
|
Phase 2 | |
| Recruiting |
NCT01754961 -
Effects of Vitamin D on Inflammation in Liver Disease
|
Phase 2 | |
| Terminated |
NCT01465516 -
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
|
N/A | |
| Completed |
NCT01265511 -
Study of SCY-635, Pegasys and Copegus in Hepatitis C
|
Phase 2 | |
| Completed |
NCT04042740 -
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05601518 -
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
|
||
| Terminated |
NCT02429583 -
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
Phase 4 | |
| Not yet recruiting |
NCT05506475 -
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
|
||
| Withdrawn |
NCT02112630 -
Boceprevir in End Stage Renal Disease (ESRD)
|
N/A | |
| Terminated |
NCT01841502 -
Interaction Between Paroxetine and Telaprevir
|
Phase 2 | |
| Completed |
NCT02076100 -
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
|
Phase 1 | |
| Terminated |
NCT01560468 -
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
|
Phase 1 | |
| Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 |